NUBEQA® (darolutamide) GUIDELINES
Funding
How much does darolutamide cost in the UK?
The cost of darolutamide is funded throughout the UK as per the National Institute for Health and Care Excellence (NICE) and Scottish Medicines Consortium (SMC) guidelines:
International Guidelines:
Is NUBEQA recommended by international guidelines?
NUBEQA is recommended by EAU guidelines:
Guidelines for non-metastatic castrate-resistant disease
Recommendation:
- Offer apalutamide, darolutamide or enzalutamide to patients with M0 CRPC and a high risk of developing metastasis (PSA-DT < 10 months) to prolong time to metastases and overall survival.
Guidelines for the first-line treatment of hormone-sensitive metastatic disease*
Recommendations:
- Offer docetaxel only in combination with ADT plus abiraterone or darolutamide to patients with M1 disease and who are fit for docetaxel.
- Offer ADT combined with darolutamide to patients with M1 disease who are fit for the regimen.
* metastatic disease defined by bone scintigraphy and CT scan/MRI.
For further information please refer to the Full EAU Guidelines.
Resources about NUBEQA in nmCRPC and mHSPC?
Clinically proven in Phase 3 studies across three indications in mHSPC and nmCRPC. Help maintain your patients' QoL. The only second-generation ARI approved for mHSPC with and without docetaxel.
Delay metastases. Extend survival.
Help maintain your patients' QoL
Abbreviations
ADT, androgen deprivation therapy; EAU, European Association of Urology; mHSPC, metastatic hormone sensitive prostate cancer; M0, non-metastatic; nmCRPC, non-metastatic castration-resistant prostate cancer; NICE, National Institute for Health and Care Excellence; PSA-DT, prostate-specific antigen-doubling time; SMC, Scottish Medicines Consortium.
PP-NUB-GB-3029 | July 2026